nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—MAOA—conduct disorder	0.894	1	CbGaD
Rizatriptan—MAOA—Enzymatic degradation of Dopamine by monoamine oxidase—COMT—conduct disorder	0.0124	0.125	CbGpPWpGaD
Rizatriptan—MAOA—Clearance of dopamine—COMT—conduct disorder	0.00899	0.0907	CbGpPWpGaD
Rizatriptan—HTR1F—Serotonin receptors—HTR2A—conduct disorder	0.00428	0.0431	CbGpPWpGaD
Rizatriptan—MAOA—Serotonin Transporter Activity—SLC6A4—conduct disorder	0.0042	0.0423	CbGpPWpGaD
Rizatriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.0041	0.0414	CbGpPWpGaD
Rizatriptan—Zolmitriptan—MAOA—conduct disorder	0.00296	0.402	CrCbGaD
Rizatriptan—HTR1F—Monoamine GPCRs—DRD4—conduct disorder	0.00292	0.0294	CbGpPWpGaD
Rizatriptan—MAOA—Dopamine metabolism—COMT—conduct disorder	0.00278	0.0281	CbGpPWpGaD
Rizatriptan—HTR1D—Serotonin receptors—HTR2A—conduct disorder	0.00274	0.0276	CbGpPWpGaD
Rizatriptan—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.00268	0.027	CbGpPWpGaD
Rizatriptan—MAOA—Biogenic Amine Synthesis—COMT—conduct disorder	0.00248	0.025	CbGpPWpGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—DRD4—conduct disorder	0.00245	0.0247	CbGpPWpGaD
Rizatriptan—Almotriptan—MAOA—conduct disorder	0.00224	0.305	CrCbGaD
Rizatriptan—Sumatriptan—MAOA—conduct disorder	0.00216	0.293	CrCbGaD
Rizatriptan—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.00204	0.0206	CbGpPWpGaD
Rizatriptan—HTR1F—Monoamine GPCRs—HTR2A—conduct disorder	0.00191	0.0192	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—DRD4—conduct disorder	0.00187	0.0188	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.00183	0.0184	CbGpPWpGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0016	0.0161	CbGpPWpGaD
Rizatriptan—HTR1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.00157	0.0158	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.00154	0.0155	CbGpPWpGaD
Rizatriptan—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.00139	0.014	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—DRD4—conduct disorder	0.0013	0.0131	CbGpPWpGaD
Rizatriptan—CYP1A2—Methylation—COMT—conduct disorder	0.00127	0.0128	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—HTR2A—conduct disorder	0.00122	0.0123	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.00119	0.012	CbGpPWpGaD
Rizatriptan—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.00117	0.0118	CbGpPWpGaD
Rizatriptan—HTR1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00102	0.0103	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.001	0.0101	CbGpPWpGaD
Rizatriptan—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.000909	0.00916	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000862	0.00869	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—HTR2A—conduct disorder	0.000846	0.00853	CbGpPWpGaD
Rizatriptan—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.000791	0.00797	CbGpPWpGaD
Rizatriptan—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000764	0.0077	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CGA—conduct disorder	0.000656	0.00662	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000649	0.00654	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—DRD4—conduct disorder	0.000607	0.00612	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000564	0.00568	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000551	0.00556	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00054	0.00544	CbGpPWpGaD
Rizatriptan—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.000536	0.00541	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000503	0.00507	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—GABRA2—conduct disorder	0.000497	0.00501	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000483	0.00487	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000428	0.00431	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CGA—conduct disorder	0.00042	0.00423	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000411	0.00415	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.000411	0.00414	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—DRD4—conduct disorder	0.000388	0.00391	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.00038	0.00383	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CGA—conduct disorder	0.000371	0.00374	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000368	0.00371	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—DRD4—conduct disorder	0.000368	0.00371	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00036	0.00363	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000353	0.00356	CbGpPWpGaD
Rizatriptan—MAOA—Biological oxidations—COMT—conduct disorder	0.000353	0.00355	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CGA—conduct disorder	0.000337	0.0034	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000322	0.00324	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000315	0.00318	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.000313	0.00316	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—COMT—conduct disorder	0.000312	0.00315	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000309	0.00311	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000309	0.00311	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000302	0.00305	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00029	0.00292	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000269	0.00271	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000262	0.00264	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000243	0.00245	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—HTR2A—conduct disorder	0.00024	0.00242	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—COMT—conduct disorder	0.000239	0.00241	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.000237	0.00239	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000235	0.00237	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.000235	0.00237	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.000232	0.00234	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00023	0.00232	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00023	0.00232	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.00023	0.00232	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000222	0.00224	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.000215	0.00217	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.000211	0.00213	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—DRD4—conduct disorder	0.000208	0.00209	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000201	0.00203	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CGA—conduct disorder	0.000199	0.00201	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000197	0.00199	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—DRD4—conduct disorder	0.000189	0.0019	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.000177	0.00178	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000175	0.00177	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.000175	0.00177	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000163	0.00165	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.000161	0.00162	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00016	0.00161	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00016	0.00161	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—WASF1—conduct disorder	0.00016	0.00161	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	0.000153	0.00155	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00015	0.00151	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.00015	0.00151	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000139	0.0014	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—HTR2A—conduct disorder	0.000136	0.00137	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CGA—conduct disorder	0.000134	0.00135	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	0.000133	0.00134	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.00013	0.00131	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00013	0.00131	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000129	0.0013	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.000128	0.00129	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CGA—conduct disorder	0.000127	0.00128	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CGA—conduct disorder	0.000125	0.00126	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—HTR2A—conduct disorder	0.000123	0.00124	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—DRD4—conduct disorder	0.000121	0.00122	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.000118	0.00119	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.000114	0.00115	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—DRD4—conduct disorder	0.000111	0.00112	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000111	0.00111	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—WASF1—conduct disorder	0.000102	0.00103	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—WASF1—conduct disorder	9.99e-05	0.00101	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	9.91e-05	0.000999	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CGA—conduct disorder	9.49e-05	0.000957	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—DRD4—conduct disorder	9e-05	0.000907	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	8.67e-05	0.000874	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	8.49e-05	0.000856	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	7.87e-05	0.000794	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	7.71e-05	0.000777	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—WASF1—conduct disorder	7.61e-05	0.000767	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HTR2A—conduct disorder	7.27e-05	0.000733	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—DRD4—conduct disorder	7.13e-05	0.000718	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—DRD4—conduct disorder	6.98e-05	0.000704	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	6.47e-05	0.000652	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—COMT—conduct disorder	6.03e-05	0.000608	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	5.87e-05	0.000592	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—DRD4—conduct disorder	5.32e-05	0.000536	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CGA—conduct disorder	4.93e-05	0.000497	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HTR2A—conduct disorder	4.65e-05	0.000469	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HTR2A—conduct disorder	4.55e-05	0.000459	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EP300—conduct disorder	3.85e-05	0.000388	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HTR2A—conduct disorder	3.47e-05	0.00035	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—EP300—conduct disorder	2.59e-05	0.000261	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EP300—conduct disorder	2.46e-05	0.000248	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EP300—conduct disorder	2.41e-05	0.000243	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—COMT—conduct disorder	2.22e-05	0.000224	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—MAOA—conduct disorder	2.21e-05	0.000223	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	2.14e-05	0.000216	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EP300—conduct disorder	1.84e-05	0.000185	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—EP300—conduct disorder	9.54e-06	9.61e-05	CbGpPWpGaD
